NanoCarrier Co., Ltd. (3NQ) Price & Analysis

0 Followers

3NQ Stock Chart & Stats

€0.72

€0.00(0.00%)

At close: Jan 08 4:00 PM EST

€0.72

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.51 - €1.15

Previous CloseN/A

Volume0.00

Average Volume (3M)772.00

Market Cap

€45.50M

Enterprise Value€4.90B

Total Cash (Recent Filing)€3.40B

Total Debt (Recent Filing)€540.24M

Price to Earnings (P/E)―

Beta0.53

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-12.48

Shares Outstanding83,221,756

10 Day Avg. Volume2,257

30 Day Avg. Volume772

Financial Highlights & Ratios

PEG Ratio-1.32

Price to Book (P/B)3.10

Price to Sales (P/S)63.30

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue Rebound & High Gross MarginsA sustained revenue rebound coupled with very high gross margins indicates the core DDS offerings have favorable unit economics. Over 2–6 months this supports durable margin sustainability and gives the company leverage to monetize partnerships and absorb R&D fixed costs as sales scale.

Licensing / Collaboration Monetization ModelA business model centered on licensing and milestone-driven collaboration reduces capital intensity and commercial risk versus solo commercialization. Durable partner-funded development can provide staged cash inflows and optionality while preserving upside through royalties if partners commercialize products.

Proprietary Micellar Nanoparticle Platform (IP)Owning a differentiated DDS platform is a structural competitive advantage: it creates repeatable licensing use-cases across multiple drug programs, supports premium gross margins, and can form durable barriers to entry if protected by IP and validated in partner studies.

Bears Say

Persistent Operating And Net LossesOngoing operating and net losses mean the company continually erodes equity and cannot self-fund growth. Over a multi-month horizon this raises financing risk, limits reinvestment in R&D or commercialization, and makes long-term strategic options (e.g., independent launches) harder to execute.

Negative Operating Cash Flow & FCFConsistent cash burn forces reliance on external financing or partner payments to sustain operations. This structural cash-flow weakness increases dilution or debt risk, constrains strategic flexibility, and makes the company vulnerable if partner payments slow over the next several months.

Rising Debt And Negative Returns On EquityMeaningful debt growth combined with persistently negative ROE signals value destruction and tighter financial flexibility. Higher leverage raises interest and covenant risk, reducing resilience to setbacks and increasing the chance that financing costs or terms worsen over 2–6 months.

NanoCarrier Co., Ltd. News

Nano Holdings Begins First-in-Human mRNA Trial Targeting Knee Osteoarthritis

NanoCarrier Co., Ltd. ( ($JP:4571) ) has provided an announcement. Nano Holdings, Inc., a Japan-based healthcare value creation...

4M ago

NANO MRNA Advances RUNX1 mRNA Clinical Trial for Osteoarthritis

The latest announcement is out from NanoCarrier Co., Ltd. ( ($JP:4571) ). NANO MRNA Co., Ltd., through its...

10M ago

3NQ FAQ

What was NanoCarrier Co., Ltd.’s price range in the past 12 months?

NanoCarrier Co., Ltd. lowest stock price was €0.51 and its highest was €1.15 in the past 12 months.

What is NanoCarrier Co., Ltd.’s market cap?

NanoCarrier Co., Ltd.’s market cap is €45.50M.

When is NanoCarrier Co., Ltd.’s upcoming earnings report date?

NanoCarrier Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 34 days.

How were NanoCarrier Co., Ltd.’s earnings last quarter?

NanoCarrier Co., Ltd. released its earnings results on May 15, 2026. The company reported -€0.021 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.021.

Is NanoCarrier Co., Ltd. overvalued?

According to Wall Street analysts NanoCarrier Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NanoCarrier Co., Ltd. pay dividends?

NanoCarrier Co., Ltd. does not currently pay dividends.

What is NanoCarrier Co., Ltd.’s EPS estimate?

NanoCarrier Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NanoCarrier Co., Ltd. have?

NanoCarrier Co., Ltd. has 83,221,756 shares outstanding.

What happened to NanoCarrier Co., Ltd.’s price movement after its last earnings report?

NanoCarrier Co., Ltd. reported an EPS of -€0.021 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.74%.

Which hedge fund is a major shareholder of NanoCarrier Co., Ltd.?

Currently, no hedge funds are holding shares in DE:3NQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NanoCarrier Co., Ltd.

NANO MRNA Co., Ltd. specializes in the discovery, advancement, and manufacturing of pharmaceutical products, employing its innovative micellar nanoparticle platform. Its biopharmaceutical pipeline is primarily geared towards addressing oncological conditions and a range of other severe illnesses. The enterprise also undertakes the full spectrum of activities for anti-cancer medications, from initial scientific investigation to market commercialization, all underpinned by its distinctive micellar nanoparticle approach. Established on June 14, 1996, by Kazunori Kataoka, Teruo Okano, and Ichiro Nakatomi, the firm maintains its principal operations in Tokyo, Japan.